leisure time -WSS

leisure time

author：explore 2025-09-28 12:49:58 - browse：7476

Cambridge: Biogen — Ruby Wallau for STAT

Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person group focused on using new types of data like those from mobile phones and smart watches, and ending a clinical trial being conducted with Apple early, STAT has learned.

Biogen confirmed the organizational change, but said it might lean even more on digital tech startups in the future.

“It’s certainly not an abandonment of digital, it’s more of a realignment of resources and priorities,” said Adam Keeney, Biogen’s executive vice president and head of corporate development. However, he later acknowledged, Biogen Digital Health, a separate entity, “would no longer continue in its current form.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： FDA authorizes Novavax’s updated Covid

hotspot

knowledge

WSS

My yearlong odyssey to get my son’s ADHD medication covered

VC firm General Catalyst wants to buy a health system

Why doctors need education on FDA device approval process

Test for long Covid? Researchers find new clue in blood samples

A virus, fished out of a lake, may have saved a man’s life

A virus, fished out of a lake, may have saved a man’s life

entertainment

leisure time

explore

Bright Health sells Medicare Advantage business to Molina

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Anesthesiologist group: stop taking Ozempic before surgery

Parkinson’s finding may lead to tests and, someday, treatments

Tori Bowie and the unacceptable rates of Black maternal death

Why Charlie Gard's case is so disturbing to Americans

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How digital therapeutics firms are pivoting after Pear's bankruptcy

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Merck, J&J, and long Covid

focus

FDA authorizes Novavax’s updated Covid

Why age limits for politicians are a terrible idea

Humana cuts profit projections as Medicare Advantage costs soar

FDA panel signals lack of confidence in Amgen cancer drug data

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Bill would stop addiction treatment from triggering child abuse inquiry

hotspot

knowledge

focus

focus